Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
Tipo del documento
Intervalo de año de publicación
1.
J Inherit Metab Dis ; 42(4): 598-607, 2019 07.
Artículo en Inglés | MEDLINE | ID: mdl-30793323

RESUMEN

Riboflavin transporter deficiency (RTD) is a rare neurological condition that encompasses the Brown-Vialetto-Van Laere and Fazio-Londe syndromes since the discovery of pathogenic mutations in the SLC52A2 and SLC52A3 genes that encode human riboflavin transporters RFVT2 and RFVT3. Patients present with a deteriorating progression of peripheral and cranial neuropathy that causes muscle weakness, vision loss, deafness, sensory ataxia, and respiratory compromise which when left untreated can be fatal. Considerable progress in the clinical and genetic diagnosis of RTDs has been made in recent years and has permitted the successful lifesaving treatment of many patients with high dose riboflavin supplementation. In this review, we first outline the importance of riboflavin and its efficient transmembrane transport in human physiology. Reports on 109 patients with a genetically confirmed diagnosis of RTD are then summarized in order to highlight commonly presenting clinical features and possible differences between patients with pathogenic SLC52A2 (RTD2) or SLC52A3 (RTD3) mutations. Finally, we focus attention on recent work with different models of RTD that have revealed possible pathomechanisms contributing to neurodegeneration in patients.


Asunto(s)
Parálisis Bulbar Progresiva/diagnóstico , Pérdida Auditiva Sensorineural/diagnóstico , Deficiencia de Riboflavina/diagnóstico , Parálisis Bulbar Progresiva/genética , Parálisis Bulbar Progresiva/terapia , Pérdida Auditiva Sensorineural/genética , Pérdida Auditiva Sensorineural/terapia , Humanos , Proteínas de Transporte de Membrana/genética , Mutación , Receptores Acoplados a Proteínas G/genética , Deficiencia de Riboflavina/genética , Deficiencia de Riboflavina/terapia
2.
J Inherit Metab Dis ; 39(4): 559-64, 2016 07.
Artículo en Inglés | MEDLINE | ID: mdl-26973221

RESUMEN

INTRODUCTION: Riboflavin (vitamin B2) is absorbed in the small intestine by the human riboflavin transporters RFVT1 and RFVT3. A third riboflavin transporter (RFVT2) is expressed in the brain. In 2010 it was demonstrated that mutations in the riboflavin transporter genes SLC52A2 (coding for RFVT2) and SLC52A3 (coding for RFVT3) cause a neurodegenerative disorder formerly known as Brown-Vialetto-Van Laere (BVVL) syndrome, now renamed to riboflavin transporter deficiency. Five years after the diagnosis of the first patient we performed a review of the literature to study the presentation, treatment and outcome of patients with a molecularly confirmed diagnosis of a riboflavin transporter deficiency. METHOD: A search was performed in Medline, Pubmed using the search terms 'Brown-Vialetto-Van Laere syndrome' and 'riboflavin transporter' and articles were screened for case reports of patients with a molecular diagnosis of a riboflavin transporter deficiency. RESULTS: Reports on a total of 70 patients with a molecular diagnosis of a RFVT2 or RTVT3 deficiency were retrieved. The riboflavin transporter deficiencies present with weakness, cranial nerve deficits including hearing loss, sensory symptoms including sensory ataxia, feeding difficulties and respiratory difficulties which are caused by a sensorimotor axonal neuropathy and cranial neuropathy. Biochemical abnormalities may be absent and the diagnosis can only be made or rejected by molecular analysis of all genes. Treatment with oral supplementation of riboflavin is lifesaving. Therefore, if a riboflavin transporter deficiency is suspected, treatment must be started immediately without first awaiting the results of molecular diagnostics.


Asunto(s)
Parálisis Bulbar Progresiva/diagnóstico , Pérdida Auditiva Sensorineural/diagnóstico , Deficiencia de Riboflavina/diagnóstico , Parálisis Bulbar Progresiva/genética , Parálisis Bulbar Progresiva/terapia , Diagnóstico Diferencial , Pérdida Auditiva Sensorineural/genética , Pérdida Auditiva Sensorineural/terapia , Humanos , Proteínas de Transporte de Membrana/genética , Técnicas de Diagnóstico Molecular , Mutación , Pronóstico , Deficiencia de Riboflavina/genética , Deficiencia de Riboflavina/terapia
3.
J Inherit Metab Dis ; 35(4): 679-87, 2012 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-22231380

RESUMEN

Riboflavin and ubiquinone (Coenzyme Q(10), CoQ(10)) deficiencies are heterogeneous groups of autosomal recessive conditions affecting both children and adults. Riboflavin (vitamin B(2))-derived cofactors are essential for the function of numerous dehydrogenases. Genetic defects of the riboflavin transport have been detected in Brown-Vialetto-Van Laere and Fazio-Londe syndromes (C20orf54), and haploinsufficiency of GPR172B has been proposed in one patient to cause persistent riboflavin deficiency. Mutations in the electron tranferring fravoprotein genes (ETFA/ETFB) and its dehydrogenase (ETFDH) are causative for multiple acyl-CoA dehydrogenase deficiency. Mutations in ACAD9, encoding the acyl-CoA dehydrogenase 9 protein were recently reported in mitochondrial disease with respiratory chain complex I deficiency. All these conditions may respond to riboflavin therapy. CoQ(10) is a lipid-soluble component of the cell membranes, where it functions as a mobile electron and proton carrier, but also participates in other cellular processes as a potent antioxidant, and by influencing pyrimidine metabolism. The increasing number of molecular defects in enzymes of the CoQ(10) biosynthetic pathways (PDSS1, PDSS2, COQ2, COQ6, COQ9, CABC1/ADCK3) underlies the importance of these conditions. The clinical heterogeneity may reflect blocks at different levels in the complex biosynthetic pathway. Despite the identification of several primary CoQ(10) deficiency genes, the number of reported patients is still low, and no true genotype-phenotype correlations are known which makes the genetic diagnosis still difficult. Additionally to primary CoQ(10) deficiencies, where the mutation impairs a protein directly involved in CoQ(10) biosynthesis, we can differentiate secondary deficiencies. CoQ(10) supplementation may be beneficial in both primary and secondary deficiencies and therefore the early recognition of these diseases is of utmost importance.


Asunto(s)
Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa/genética , Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa/terapia , Deficiencia de Riboflavina/genética , Deficiencia de Riboflavina/terapia , Riboflavina/genética , Ubiquinona/análogos & derivados , Estudios de Asociación Genética , Humanos , Deficiencia Múltiple de Acil Coenzima A Deshidrogenasa/metabolismo , Mutación , Riboflavina/metabolismo , Deficiencia de Riboflavina/metabolismo , Ubiquinona/deficiencia , Ubiquinona/genética , Ubiquinona/metabolismo , Vitaminas/genética , Vitaminas/metabolismo
4.
J Dairy Sci ; 88(10): 3435-42, 2005 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-16162516

RESUMEN

Riboflavin deficiency is common in many parts of the world, particularly in developing countries. The use of riboflavin-producing strains in the production of dairy products such as fermented milks, yogurts, and cheeses is feasible and economically attractive because it would decrease the costs involved during conventional vitamin fortification and satisfy consumer demands for healthier foods. The present study was conducted to assess in a rat bioassay the response of administration of milk fermented by modified Lactococcus lactis on the riboflavin status of deficient rats. Rats were fed a riboflavin-deficient diet during 21 d after which this same diet was supplemented with milk fermented by Lactoccus lactis pNZGBAH, a strain that overproduces riboflavin during fermentation. The novel fermented product, with increased levels of riboflavin, was able to eliminate most physiological manifestations of ariboflavinosis, such as stunted growth, elevated erythrocyte glutathione reductase activation coefficient values and hepatomegaly, that were observed using a riboflavin depletion-repletion model, whereas a product fermented with a nonriboflavin-producing strain did not show similar results. A safety assessment of this modified strain was performed by feeding rodents with the modified strain daily for 4 wk. This strain caused no detectable secondary effects. These results pave the way for analyzing the effect of similar riboflavin-overproducing lactic acid bacteria in human trials. The regular consumption of products with increased levels of riboflavin could help prevent deficiencies of this essential vitamin.


Asunto(s)
Productos Lácteos Cultivados/microbiología , Lactococcus lactis/genética , Lactococcus lactis/metabolismo , Deficiencia de Riboflavina/terapia , Riboflavina/biosíntesis , Animales , Productos Lácteos Cultivados/química , Fermentación , Hígado/patología , Estado Nutricional , Tamaño de los Órganos , Organismos Modificados Genéticamente , Ratas , Ratas Wistar , Riboflavina/análisis , Riboflavina/sangre , Riboflavina/genética
5.
J Hum Nutr Diet ; 14(5): 365-70, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11906577

RESUMEN

Three cases of clinical riboflavin deficiency are reported in children aged 2-10 years attending a regional Cystic Fibrosis clinic. Riboflavin deficiency presented as angular stomatitis in all three patients. Patients were confirmed to be riboflavin deficient by assaying the activity of erythrocyte glutathione reductase. Patients were not on routine supplements of water-soluble vitamins before presentation and were treated with riboflavin supplements as part of a water-soluble vitamin complex. At presentation, one patient had poor nutritional status, but two patients were adequately nourished, receiving overnight Gastrostomy feeds. Data on these two patients indicate an adequate dietary intake of riboflavin, suggesting a mechanism for increased requirements, inadequate absorption or utilization. Additional deficiencies of thiamin, pyridoxine and iron were also observed. This paper reports the occurrence of a vitamin deficiency not previously reported in the cystic fibrosis population.


Asunto(s)
Fibrosis Quística/complicaciones , Glutatión Reductasa/metabolismo , Deficiencia de Riboflavina/etiología , Adolescente , Niño , Suplementos Dietéticos , Femenino , Humanos , Lactante , Masculino , Necesidades Nutricionales , Deficiencia de Riboflavina/diagnóstico , Deficiencia de Riboflavina/terapia , Estomatitis/diagnóstico , Estomatitis/etiología , Estomatitis/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA